Status:
NO_LONGER_AVAILABLE
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
Lead Sponsor:
ProgenaBiome
Collaborating Sponsors:
Microbiome Research Foundation
Conditions:
Neuroblastoma
Neuroblastoma (NB)
Eligibility:
All Genders
5+ years
Brief Summary
This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment
Detailed Description
Patients with neurobastoma and concurrent dysbiosis showing a bifidobacteria-bacteroides gap will undergo fecal microbiota transplant as an adjunctive to standard-of-care oncology treatment.
Eligibility Criteria
Inclusion
- willingness of parent/guardian to sign ICF
- diagnosis of neuroblastoma
- dysbiosis of the gut microbiome
Exclusion
- parent/guardian unwilling to sign ICF
- dysbiosis does not show a bifidobaceteria-bacteroides gap
- severely abnormal screening lab values
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT07223606
Last Update
November 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ProgenaBiome
Ventura, California, United States, 93003